In this discussion with Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center, she illustrates how Vanderbilt works to specify each individual patient’s cancer care regimen and treatment path.
Earlier this year, for a oncology-focused Institute for Value-Based Medicine® event, The American Journal of Managed Care® partnered with several prominent health care institutions from across the Nashville region to elevate value in cancer care by discussing the roles that academic, hospital, and community partnerships; precision medicine; pharmacy; and health equity fulfill when delivering care in the oncology space.
Lipscomb University and Metropolitan General Hospital, Meharry Medical College, Sarah Cannon, Tennessee Oncology, Thyme Care, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, and West Cancer Center were represented.
In this discussion with Cathy Eng, MD, FACP, FASCO, codirector, GI Oncology; coleader, GI Cancer Research Program; and director, Young Adult Cancers Program, Vanderbilt-Ingram Cancer Center, she illustrates how Vanderbilt works to specify each individual patient’s cancer care regimen and treatment path. Eng participated on the panel discussion, “Health Equity in Cancer Care Delivery.”
This transcript has been lightly edited for clarity; captions were auto-generated.
Transcript
How does Vanderbilt integrate its mission to elevate cancer care across its care offerings?
I would say that Vanderbilt-Ingram Cancer Center and the Vanderbilt University Medical Center—because many of our consultants are part of the university medical center—what we truly try to do for our cancer patients is really try to focus on their unmet needs. Especially in regards to cancer treatment nowadays, the focus of a lot of therapy is more personalized, biomarker-driven therapy.
I think because we are fortunate enough to be a large academic institution, we have good rapport with pharma, and as a result, have historically been involved in many pivotal clinical trials. Just for the audience, I'm largely a GI [gastrointestinal] medical oncology specialist, but I do assist with strategic initiatives regarding pharma interests in the cancer center itself.
I think that when we're talking about elevating value in cancer care, I think it's really important to try to be able to offer patients care more specific to their malignancy. We recognize the importance that in the majority, at least solid tumors, next-generation sequencing or mutation analysis, or any type of amplification or any type of fusion protein, is noted based upon the patient's existing tumor, and we will work with other companies to identify those various molecular alterations. That way we can provide patients the most optimal care in regards to treatment.
But also, I think the value arises when we work very much so in a multidisciplinary team effort with our surgical colleagues, radiation colleagues, pathology, etc, and a lot of our treatment planning is discussed in our tumor board, so you're getting multiple opinions of people, even though you may have only had 1 consultation with 1 doctor—you're getting multiple opinions within 1 meeting about the best approach to your cancer. I think that that really helps optimize the value for a cancer care patient, plus all the supportive services that are available at Vanderbilt, such as social work, supportive care, oncology clinic, to optimize the overall well-being of the patient, nutrition, wound care, etc.
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Culture Key to Data Collection of Sexual Orientation and Gender Identity in Cancer Care
June 23rd 2025This research highlights the key factors, like leadership buy-in, mandatory protocols, and electronic health record workflows, that influence the effective collection of data on sexual orientation and gender identity in outpatient oncology clinics to improve patient-centered care.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More